Skip to main content Skip to footer
ABLi Therapeutics, Inc. Corporate Page
  • About Us
  • Pipeline
  • Clinical Trials
  • Risvodetinib
  • Team
  • Publications
  • News
  • Contact Us

Explore our research and learn more about the science backing our approach.

A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease
Mar 19, 2024
The c-Abl inhibitor Risvodetinib (ABLi-148009) suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease
Jan 18, 2023
Parkinson’s Disease Modification through Abl Kinase Inhibition: An Opportunity
Nov 1, 2021
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease
Nov 1, 2020
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s disease
Sep 1, 2020
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease
Sep 1, 2019
©2025 ABLi Therapeutics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap